# FLX475 in Combination With Ipilimumab in Advanced Melanoma

> **NCT04894994** · PHASE2 · TERMINATED · sponsor: **RAPT Therapeutics, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** FLX475
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04894994
- **Lead sponsor:** RAPT Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-03
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Change in clinical landscape
- **Last updated:** 2023-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894994, "FLX475 in Combination With Ipilimumab in Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04894994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*